Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  alemtuzumab
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
AP1903 and Genetically Modified Donor T Cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2012-0501, NCI-2013-01666, NCT01875237
Donor Stem Cell Transplant in Treating Patients With Hematological Malignancies Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 25 and under
Trial IDs: MOHEL, NCI-2012-00807, H-8701, NCT00368355
Alemtuzumab and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 10H06, NCI-2011-00514, 2010-024389-23, STU00044115, 114813, 114699, NCT01361711
Nonmyeloablative Donor Stem Cell Transplant in Treating Patients with Congenital Anemias including Sickle Cell Disease and Thalassemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 55
Trial IDs: 012013-015, NCI-2014-02134, NCT02038478
Alemtuzumab, Etoposide, and Dexamethasone in Treating Patients with Hemophagocytic Lymphohistiocytosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2014-0989, NCI-2015-00526, 00000363, NCT02385110
Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 2 to 21
Trial IDs: RADIANT, NCI-2012-00588, NCT01625351
Donor Lymphocyte Infusion in Treating Patients Previously Treated with Donor Stem Cell Transplant
Status: Active
Phase: Phase I
Type: Supportive care
Age: 18 and over
Trial IDs: Pro00003975, NCI-2013-00567, NCT01627275
Recombinant Human Interleukin-15 and Alemtuzumab in Treating Patients with Refractory or Relapsed Chronic or Acute Adult T-Cell Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0062, NCI-2016-00195, P152447, 10004, NCT02689453
CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Status: Active
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Start Over